Ozempic vs Wegovy vs Mounjaro: 2026 Comparison
Photo by Michael Burrows on Pexels
GLP-1 and GIP/GLP-1 receptor agonists have reshaped clinical conversations about type 2 diabetes and chronic weight management since 2021. Three brand names dominate US prescribing in 2026: Ozempic and Wegovy (both semaglutide, made by Novo Nordisk) and Mounjaro (tirzepatide, made by Eli Lilly). A fourth, Zepbound, shares tirzepatide with Mounjaro but is FDA-approved for weight loss in eligible adults.
This article compares the three drugs neutrally — what each is FDA-approved for, what major trials showed, common side effects, and typical 2026 cash prices. It is not a recommendation. Prescribing decisions belong to a licensed physician who has reviewed your full medical history.
Important: Weight-loss medications are prescription drugs with potential side effects. They are FDA-approved for specific indications and BMI thresholds. This article describes them neutrally for educational purposes. Always consult a licensed physician — never obtain GLP-1 or other weight-loss medications outside a regulated prescribing relationship.
How This Guide Works
We pulled FDA labeling, NIH summaries, and the published STEP and SURMOUNT trial programs to compare each medication on indication, mechanism, dosing schedule, average trial outcomes, common adverse events, and 2026 US pricing. Where evidence is mixed or evolving, we say so. We do not estimate “best” for individual readers — that decision depends on diagnosis, comorbidities, insurance, contraindications, and prescriber judgment.
Quick Comparison
| Drug | Active Ingredient | FDA-Approved Indication (US) | Maker | Route | Typical Cash Price (2026) |
|---|---|---|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes (adults) | Novo Nordisk | Weekly injection | ~$970/mo |
| Wegovy | Semaglutide | Chronic weight management (BMI ≥30, or ≥27 + comorbidity) | Novo Nordisk | Weekly injection | ~$1,350/mo |
| Mounjaro | Tirzepatide | Type 2 diabetes (adults) | Eli Lilly | Weekly injection | ~$1,070/mo |
| Zepbound (related) | Tirzepatide | Chronic weight management (same BMI thresholds) | Eli Lilly | Weekly injection | ~$1,060/mo |
Note: Ozempic is FDA-approved for type 2 diabetes; using it for weight loss alone is off-label. Wegovy and Zepbound are the weight-management-specific brands of the same molecules.
What Each Drug Does
Ozempic (semaglutide)
Ozempic activates GLP-1 receptors, which slows gastric emptying, improves insulin secretion in response to food, and reduces appetite signaling. The FDA approval is for adults with type 2 diabetes, often as second-line therapy when metformin alone is insufficient.
Wegovy (semaglutide)
Wegovy is the same molecule as Ozempic but at a higher maintenance dose (2.4 mg weekly) and is FDA-approved for chronic weight management in adults whose BMI is 30 or higher, or 27 or higher with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. The STEP 1 trial showed an average ~15% reduction in body weight at 68 weeks among participants taking semaglutide alongside lifestyle support, compared with about 2.4% with placebo.
Mounjaro (tirzepatide)
Mounjaro is a dual GIP/GLP-1 receptor agonist that targets two incretin pathways simultaneously. It is FDA-approved for type 2 diabetes in adults. The SURMOUNT-1 trial, which used tirzepatide for weight management (the Zepbound indication), showed average weight reductions of about 20% at 72 weeks on the 15 mg dose.
Zepbound (tirzepatide)
Zepbound is the same molecule as Mounjaro and was FDA-approved in late 2023 for chronic weight management in adults at the same BMI thresholds as Wegovy.
Trial Outcomes Snapshot
| Trial | Drug | Population | Average Weight Change | Duration |
|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg | Adults with overweight/obesity, no T2D | ~-14.9% | 68 wks |
| STEP 2 | Semaglutide 2.4 mg | Adults with T2D and obesity | ~-9.6% | 68 wks |
| SURMOUNT-1 | Tirzepatide 15 mg | Adults with overweight/obesity, no T2D | ~-20.9% | 72 wks |
| SURPASS-2 | Tirzepatide 15 mg vs semaglutide 1 mg | Adults with T2D | Tirzepatide ~-11.2% vs semaglutide ~-5.7% | 40 wks |
These are averages from controlled trials with lifestyle support. Individual results vary widely. Trial participants typically had ongoing dietitian and clinician contact, which influences outcomes.
Common Side Effects
GLP-1 receptor agonists share a class side-effect profile dominated by gastrointestinal symptoms, especially during dose escalation.
- Nausea (very common, often improves over weeks)
- Vomiting, diarrhea, constipation
- Reduced appetite (intended effect; can be excessive in some)
- Injection-site reactions
- Fatigue, headache
Less common but clinically important:
- Pancreatitis (rare; stop medication and seek care for severe abdominal pain)
- Gallbladder disease, including gallstones
- Gastroparesis (delayed gastric emptying that persists)
- Kidney injury, often secondary to dehydration from GI symptoms
- Possible thyroid C-cell tumor signal (boxed warning; contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2)
- Hypoglycemia, primarily when combined with insulin or sulfonylureas
Stop the medication and contact your physician if you experience severe or persistent abdominal pain, signs of dehydration, vision changes (in patients with diabetic retinopathy), or symptoms suggestive of pancreatitis.
Cost, Insurance, and Access in 2026
| Medication | Typical Cash | With Eligible Commercial Insurance | Manufacturer Savings |
|---|---|---|---|
| Wegovy | ~$1,350/mo | As low as $25/mo (varies) | Novo Nordisk savings card |
| Ozempic | ~$970/mo | Varies; often covered for T2D | Novo Nordisk savings card |
| Mounjaro | ~$1,070/mo | Varies; often covered for T2D | Lilly savings card |
| Zepbound | ~$1,060/mo | Varies for weight indication | Lilly savings card |
Medicare generally does not cover weight-loss medications when used solely for weight loss, though coverage is evolving. Many commercial plans require prior authorization, step therapy, or a documented BMI and comorbidity. The cash price is a list reference and is not what most patients pay through a regulated pharmacy with insurance or savings programs.
How to Talk to Your Doctor
- Bring a complete medication and supplement list, including any over-the-counter products.
- Share your personal and family history, especially of thyroid cancer, pancreatitis, gallbladder disease, kidney disease, and eating disorders.
- Ask about non-medication options and how they compare for your situation.
- Ask what side effects to watch for and when to call back.
- Confirm follow-up cadence, labs, and how dose adjustments will be made.
Recommended Offers
💡 Editor’s pick — Telehealth obesity medicine: Form Health connects you with board-certified obesity-medicine physicians who can determine if medication is appropriate for your situation.
💡 Editor’s pick — Combined behavior + medical: Sequence by Weight Watchers pairs clinician oversight with the WW behavior program for eligible adults.
💡 Editor’s pick — Foundations first: If you are not sure medication is right for you, Found’s Foundations track focuses on nutrition, sleep, movement, and behavior change without medication.
FAQ — Ozempic, Wegovy, Mounjaro
Q: Are these drugs interchangeable? A: No. They have different FDA-approved indications, dosing schedules, and ingredients. Your physician chooses based on diagnosis, comorbidities, and access.
Q: Can I get them online without a prescription? A: No. They are prescription-only. Compounded versions sold outside a regulated prescribing relationship carry significant safety risks and have been the subject of FDA warnings.
Q: How long do I take them? A: Trial data suggests most weight is regained when these medications are stopped without ongoing lifestyle support. Duration is a clinical decision with your physician.
Q: Do they replace diet and exercise? A: No. Trial protocols included structured lifestyle support. Sustainable outcomes pair medication with nutrition, movement, and behavioral changes.
Q: What about generics or compounded versions? A: As of 2026, there is no FDA-approved generic semaglutide or tirzepatide. Compounded versions are not FDA-approved drugs and have been associated with dosing errors.
Q: Are there non-injectable options? A: Rybelsus is an oral semaglutide approved for type 2 diabetes; oral weight-loss formulations are in development. Discuss alternatives with your physician.
Related Reading on Righte Hub
- Weight Loss Medications Overview for 2026
- Best Medical Weight Loss Programs 2026
- Best Weight Loss Programs of 2026
- Sustainable Weight Loss: Evidence-Based 2026 Guide
- Weight Loss After 40: Realistic Guide for 2026
Final Verdict
Ozempic, Wegovy, and Mounjaro are three of the most studied medications in modern endocrinology, with strong but heterogeneous effects on body weight and glycemic outcomes. They are not lifestyle products. The right choice — if any — depends on your diagnosis, history, insurance, and prescriber’s judgment. Treat this article as a starting point for a real conversation with a licensed physician.
This article is for informational and educational purposes only and is not medical, dietary, or weight-loss advice. Talk to a licensed healthcare professional or registered dietitian before starting any weight-management program, especially if you have any medical conditions or take prescription medications. Righte Hub may receive compensation for some placements; rankings are independent.
By Righte Hub Editorial · Updated May 9, 2026
- weight loss
- GLP-1 medications
- 2026
- wellness